In this regard, we found that cirmtuzumab could block the capacity of Wnt5a to induce ROR1 to complex and phosphorylate cortactin, recruit ARHGEF1, and activate RhoA, thereby suppressing breast-cancer-cell migration/metastasis. Here, WNT5A is linked to breast carcinoma.